Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Obesity Intervention: A New Era Of Discovery And Innovation

Executive Summary

Driven by a vast and underserved market in dire need of safer, less-invasive, more effective solutions, manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease. Indeed the obesity intervention paradigm is rapidly changing as ongoing research provides new insights into the underlying mechanisms behind obesity and bariatric surgery, heralding a new era where the primary treatment target for bariatric surgery is becoming disease specific, rather than targeted at obesity alone.

You may also be interested in...

Apollo Endosurgery Wants Lap-Band To Become Even More Of An Asset

At the end of October, Apollo Endosurgery announced that it would acquire certain obesity assets from Allergan: Lap-Band, one of the most well-known brands in bariatric surgery, and Orbera, Allergan’s intra-gastric balloon system, the leading such product in Europe. It’s not unusual these days for large companies to unload under-performing businesses, but the Allergan deal is striking because of its choice of partner – Apollo Endosurgery is a small organization acquiring a much larger one.

USGI Medical Receives IDE To Test Incisionless Weight Loss Procedure

USGI Medical received a conditional investigational device exemption from FDA to test its catheter for treating obesity using an incisionless, endoscopic procedure.

Endo Tools Therapeutics SA: Enabling Natural Orifice GI Procedures

Belgium-based Endo Tools Therapeutics SA is developing devices that will enable NOTES procedures to treat disorders such as type 2 diabetes, morbid obesity, and digestive tract tumors. Its Endomina device is a universal, multi-channel triangulation platform for use on any existing endoscope through the natural orifices, such as the esophagus.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts